NCT04965064 2025-12-15Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 SignalingUniversity of RochesterPhase 2 Recruiting22 enrolled